INTELLECTUAL PROPERTY — EXTIMA® / SAGOL INC.
EXTIMA® and all associated system architectures, neuromorphic interface concepts, biosensing frameworks, device schematics, and visual assets are protected under a unified global IP framework owned by Vitalii Gavrylytsia and exclusively licensed to Sagol Inc. (Delaware, USA).
IP Portfolio Includes:
– Neuromorphic biosensing system architecture
– Predictive cognitive-state modeling logic
– Human-state intervention and response interface
– Device schematics, industrial design, and visual assets
– Registered Trademark EXTIMA® (Classes 9, 10, 42, 44)
Patent Status:
– Multiple Provisional Patent Applications (PPA) filed and priority secured
under the Paris Convention (179+ countries).
– Conversion to PCT and National Phase filings scheduled according to the
statutory timeline.
– Full technical documentation available under NDA for accredited investors
and strategic partners.
Trademark Protection:
– EXTIMA® registered through the UK IPO.
– Eligible for expansion under the Madrid Protocol for global jurisdictional coverage.
Copyright:
– Core visual materials (including FIG.1 and MVP renders) registered and
protected under the Berne Convention (global copyright recognition).
Corporate:
Sagol Inc. — Delaware, USA (Active Corporate Status)
– EIN: Registered and Active (U.S. Federal Tax Authority)
– D-U-N-S: Registered and Active (Dun & Bradstreet Global Index)
– Banking & Infrastructure: Mercury (U.S. regulated partner banking)
Usage & Enforcement:
Sagol Inc. retains exclusive worldwide rights to use, license, defend, and enforce
the EXTIMA® system, brand, and IP portfolio. Any reproduction, redistribution, or
derivative usage is strictly prohibited without explicit written authorization.
© 2025 Sagol Inc. / EXTIMA® — All Rights Reserved.